Literature DB >> 14551139

Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein.

Judy Wai Ping Yam1, Dong-Yan Jin, Chi Wai So, Li Chong Chan.   

Abstract

The chimeric MLL-EEN fusion protein is created as a result of chromosomal translocation t(11;19)(q23;p13). EEN, an Src homology 3 (SH3) domain-containing protein in the endophilin family, has been implicated in endocytosis, although little is known about its role in leukemogenesis mediated by the MLL-EEN fusion protein. In this study, we have identified and characterized EBP, a novel EEN binding protein that interacts with the SH3 domain of EEN through a proline-rich motif PPERP. EBP is a ubiquitous protein that is normally expressed in the cytoplasm but is recruited to the nucleus by MLL-EEN with a punctate localization pattern characteristic of the MLL chimeric proteins. EBP interacts simultaneously with EEN and Sos, a guanine-nucleotide exchange factor for Ras. Coexpressoin of EBP with EEN leads to suppression of Ras-induced cellular transformation and Ras-mediated activation of Elk-1. Taken together, our findings suggest a new mechanism for MLL-EEN-mediated leukemogenesis in which MLL-EEN interferes with the Ras-suppressing activities of EBP through direct interaction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551139     DOI: 10.1182/blood-2003-07-2452

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Essential role of SH3GL1 in interleukin-6(IL-6)- and vascular endothelial growth factor (VEGF)-triggered p130cas-mediated proliferation and migration of osteosarcoma cells.

Authors:  En-Qi Li; Jin-Li Zhang
Journal:  Hum Cell       Date:  2017-07-12       Impact factor: 4.174

2.  Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis.

Authors:  Kumud R Poudel; Minna Roh-Johnson; Allen Su; Thuong Ho; Haritha Mathsyaraja; Sarah Anderson; William M Grady; Cecilia B Moens; Maralice Conacci-Sorrell; Robert N Eisenman; Jihong Bai
Journal:  Dev Cell       Date:  2018-06-18       Impact factor: 12.270

Review 3.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

4.  JISTIC: identification of significant targets in cancer.

Authors:  Felix Sanchez-Garcia; Uri David Akavia; Eyal Mozes; Dana Pe'er
Journal:  BMC Bioinformatics       Date:  2010-04-14       Impact factor: 3.169

5.  RACK1, a new ADAM12 interacting protein. Contribution to liver fibrogenesis.

Authors:  Katia Bourd-Boittin; Hélène Le Pabic; Dominique Bonnier; Annie L'Helgoualc'h; Nathalie Théret
Journal:  J Biol Chem       Date:  2008-07-11       Impact factor: 5.157

6.  SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway.

Authors:  Haitao Guan; Ping Zhao; Zhijun Dai; Xiaoxu Liu; Xijing Wang
Journal:  Tumour Biol       Date:  2016-05-24

7.  Subcellular localization of EEN/endophilin A2, a fusion partner gene in leukaemia.

Authors:  Ngai Cheung; Chi Wai So; Judy W P Yam; C K C So; Randy Y C Poon; Dong-Yan Jin; Li Chong Chan
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

8.  Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas.

Authors:  Tomoo Matsutani; Takaki Hiwasa; Masaki Takiguchi; Takashi Oide; Mitoshi Kunimatsu; Naokatsu Saeki; Yasuo Iwadate
Journal:  J Exp Clin Cancer Res       Date:  2012-10-11

Review 9.  The robotic mouse: unravelling the function of AF4 in the cerebellum.

Authors:  Emmanuelle Bitoun; Kay Elizabeth Davies
Journal:  Cerebellum       Date:  2005       Impact factor: 3.648

10.  Endosomal crosstalk: meeting points for signaling pathways.

Authors:  Máté Pálfy; Attila Reményi; Tamás Korcsmáros
Journal:  Trends Cell Biol       Date:  2012-07-14       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.